<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708990</url>
  </required_header>
  <id_info>
    <org_study_id>Y (2020) 044</org_study_id>
    <nct_id>NCT04708990</nct_id>
  </id_info>
  <brief_title>DELP for Acute Hemorrhagic Stroke</brief_title>
  <official_title>DELP for Acute Hemorrhagic Stroke: a Prospective, Random, Open-label, Blind-endpoint, Single Centre, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve&#xD;
      neurological function and life ability of AIS patients and approved for the treatment of AIS&#xD;
      by China Food and Drug Administration (CFDA). Our recent study imply that the neuroprotective&#xD;
      effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free&#xD;
      radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, we argue that&#xD;
      DELP may exert neuroprotective effect on acute cerebral hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the research sponsors stopped further funding due to a planning of a multi-center trial&#xD;
  </why_stopped>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in national institutes of health stroke scale (NIHSS)</measure>
    <time_frame>48 hours</time_frame>
    <description>NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of hematoma volume compared with the baseline</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of edema volume around hematoma compared with the baseline</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of death due to any cause</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>DELP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delipid Extracorporeal Lipoprotein filter from Plasma</intervention_name>
    <description>As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke</description>
    <arm_group_label>DELP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-80;&#xD;
&#xD;
          -  Spontaneous cerebral hemorrhage;&#xD;
&#xD;
          -  Deep supratentorial intracerebral hemorrhage (basal ganglia and thalamus) with&#xD;
             hematoma volume 5-40ml;&#xD;
&#xD;
          -  NIHSS: 4-22;&#xD;
&#xD;
          -  Time from onset to DELP is less than 48 hours;&#xD;
&#xD;
          -  Premorbid mRS 0 or 1;&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary cerebral hemorrhage (secondary to trauma, tumor, vascular malformation,&#xD;
             hemorrhage transformation of ischemic stroke, etc.);&#xD;
&#xD;
          -  Comatose patients on admission (GCS score 3-8 on the Glasgow Coma Scale);&#xD;
&#xD;
          -  Patients with intracerebral hemorrhage ruptured into the ventricle;&#xD;
&#xD;
          -  Planed surgery;&#xD;
&#xD;
          -  Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          -  Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure&#xD;
             over 110 mmHg);&#xD;
&#xD;
          -  Previous allergy to heparin or calcium;&#xD;
&#xD;
          -  hypoproteinemia;&#xD;
&#xD;
          -  Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

